GSGTF (Gensight Biologics) Accounts Payable: $6.93 Mil (As of Dec. 2025)


What is Gensight Biologics Accounts Payable?

Gensight Biologics GSGTF Accounts Payable is $6.93 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Gensight Biologics's Accounts Payable for the quarter that ended in Dec. 2025 was $6.93 Mil.

Gensight Biologics's quarterly Accounts Payable increased from Dec. 2024 ($6.66 Mil) to Jun. 2025 ($9.88 Mil) but then declined from Jun. 2025 ($9.88 Mil) to Dec. 2025 ($6.93 Mil).

Gensight Biologics's annual Accounts Payable increased from Dec. 2023 ($6.14 Mil) to Dec. 2024 ($6.66 Mil) and increased from Dec. 2024 ($6.66 Mil) to Dec. 2025 ($6.93 Mil).

Gensight Biologics Accounts Payable Related Terms

Gensight Biologics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Accounts Payable Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.06 8.28 6.14 6.66 6.93

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.14 5.15 6.66 9.88 6.93

Gensight Biologics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $6.93 Mil mean?
Gensight Biologics (GSGTF) has a Accounts Payable of $6.93 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Gensight Biologics and its competitors.
Is Gensight Biologics' Accounts Payable too high?
Gensight Biologics' current Accounts Payable is $6.93 Mil.
How does Gensight Biologics' Accounts Payable compare to VRTX and REGN?
Gensight Biologics' Accounts Payable of $6.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Accounts Payable is $6.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current Accounts Payable is $6.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Accounts Payable is $6.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.